metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-118 METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: INDICATION FOR L...
Journal Information
Vol. 29. Issue S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(December 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(December 2024)
Full text access
P-118 METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: INDICATION FOR LIVER TRANSPLANTATION AND OCCURRENCE IN THE POSTOPERATIVE PERIOD
Visits
11
Felipe Ramos Caprini1, Guilherme Massote Fontanini2, Juarez Roberto de Oliveira Vasconcelos2, Fernanda Fernandes Souza3, Ajith Kumar Sankarankutty4, Marcia Guimarães Villanova2, Roberta Chaves Araújo3
1 Hospital das Clínicas of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil
2 Gastroenterology Division, Hospital das Clínicas of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil
3 Professor of the Division of Gastroenterology, Department of Clinical Medicine at Faculty of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil
4 Division of Digestive Surgery, Department of Surgery and Anatomy at Faculty of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 29. Issue S3

Abstracts of the 2023 Annual Meeting of the ALEH

More info
Conflict of interest

No

Introduction and Objectives

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most important causes of liver disease worldwide, and it is currently the main indication for liver transplantation.

This study aims to evaluate (1) clinical-epidemiological profile of patients listed for liver transplant due to MASLD-related cirrhosis and mortality on the waiting list; (2) occurrence of allograft steatosis and new post-transplant comorbidities; (3) survival of patients with and without MASLD in the postoperative period.

Patients / Materials and Methods

This retrospective study is based on a review of medical records of patients treated at the Liver Transplant outpatient clinic of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto - University of São Paulo, from 2005 to 2015.

Results and Discussion

Of all patients listed for liver transplant (610), 10% had MASLD-related cirrhosis. Of these, 47.5% were female, with an average age of 56.3 years. These patients had higher MELD values (P = 0.01), higher rates of metabolic syndrome (P<0.05), and waiting list mortality of 42.6%. About transplant patients (264), 58 developed hepatic steatosis post-transplant, 82.8% of these with new steatosis and 17.2% with MASLD recurrence. The development of new comorbidities, such as diabetes and systemic arterial hypertension, was present in 26.2% and 22.5% of transplant recipients. Obesity and hypertension were the variables associated with a greater risk of allograft steatosis. The average survival of patients undergoing surgery was 8.7 years. Individuals transplanted for MASLD had significantly lower survival than those with other causes of cirrhosis (P=0.05).

Conclusions

As MASLD is a highly prevalent disease, with different local realities, studies like this can serve as a basis for understanding the local reality and provide important information for developing public health programs.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos